Tridosil

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tridosil

Quick Facts

Property Description
Active Ingredient Azithromycin
Pharmacological Class Azalide Antibiotic (Macrolide subclass)
Common Use Treating bacterial infections
Origin Semi-synthetic
Route of Administration Oral or Intravenous

Tridosil is a pharmaceutical preparation classified as a broad-spectrum antibiotic used to control infections caused by susceptible bacteria. It is a prescription medicine intended for systemic use, meaning it acts throughout the body to eliminate harmful microorganisms.


Defining Tridosil: An Azalide Anti-Infective Agent

Tridosil is an Anti-Infective Agent containing the active ingredient Azithromycin. Chemically, Azithromycin is defined as an azalide antibiotic, a distinct subclass of the macrolide antibiotic group. This azalide modification provides enhanced stability against stomach acid and contributes to a profile distinct from older macrolides. Azithromycin is a semi-synthetic compound, derived from the natural macrolide Erythromycin but structurally altered for improved properties.


Composition, Forms, and General Therapeutic Purpose

The core composition of Tridosil features Azithromycin, often formulated as Azithromycin Dihydrate, along with necessary pharmaceutical excipients and vehicles. Azithromycin is characterized by its prolonged presence in tissue and high tissue penetration. It is available in various dosage forms and route(s) of administration, including tablets for standard oral use, oral suspensions (often formulated for pediatric patients), and a lyophilized powder intended for intravenous (IV) infusion in hospital settings. The general therapeutic purpose of Tridosil is to disrupt the life cycle of bacteria by interfering with their ability to build essential proteins, which stalls the growth and multiplication of the bacterial population.

Regulatory References

  1. National Institutes of Health (NIH) MedlinePlus

What side effects are possible with Tridosil?

Possible Side Effects and Safety Information

The safety profile of Tridosil (Azithromycin) is formally documented by regulatory agencies, classifying potential adverse reactions by frequency and the physiological system affected.

Frequency-Classified Adverse Reactions

Adverse reactions are classified according to standard regulatory frequency bands:

  • Very Common: Gastrointestinal disturbances, with diarrhoea being the most frequently reported effect.
  • Common: Effects such as headache, nausea, vomiting, and abdominal pain are generally observed.
  • Uncommon: Reactions classified here include dizziness, insomnia, rash, and minor hypersensitivity reactions.

System-Organ Class and Serious Reactions

Safety concerns are grouped by System-Organ Classes (SOC), including the Gastrointestinal, Nervous System, Hepatobiliary, and Cardiac systems.

The regulatory labels identify several reactions classified as serious adverse reactions. These include the risk of QT interval prolongation which may lead to a fatal heart rhythm irregularity known as Torsades de pointes. Cases of severe hepatotoxicity, including reports of fatal hepatic failure, and severe skin reactions such as Stevens-Johnson Syndrome (SJS) are also documented safety concerns. Clostridioides difficile-Associated Diarrhoea (CDAD) is listed as a potential serious gastrointestinal reaction.

Population-Specific Safety Constraints

Official prescribing information includes specific limitations regarding use in certain populations. Use is constrained in individuals with a prior history of cholestatic jaundice or hepatic dysfunction associated with Azithromycin. Particular caution is specified for patients with known QT interval prolongation or other cardiac risk factors, and in those with severe hepatic impairment. Furthermore, Azithromycin may exacerbate muscle weakness in persons with Myasthenia gravis.

Exposure-Related Safety Notes

Some effects, such as gastrointestinal disturbances, are noted in regulatory documents as potentially being more common at the start of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory documents indicate that overdosage with Tridosil (Azithromycin) may result in an increase in the severity of adverse events observed at therapeutic doses. The documented clinical manifestations primarily involve severe gastrointestinal disturbances, including intense nausea, vomiting, and diarrhea, along with the potential for reversible loss of hearing.

The overdose profile highlights the risk of serious cardiovascular toxicity. Overdosage can lead to a prolongation of the heart’s QT interval, which carries the risk of developing potentially fatal arrhythmias, such as Torsades de pointes. Patients with pre-existing heart conditions or low electrolyte levels are recognized as being at particular risk for these life-threatening events.

Because of the potential for severe, life-threatening outcomes, regulatory authorities mandate that immediate medical attention or the poison control helpline be contacted upon suspected overdosage. Emergency services must be called immediately if the affected individual has collapsed, experienced a seizure, or is having trouble breathing. No specific antidote is known for Tridosil overdosage; therefore, clinical management focuses on general symptomatic and supportive measures and may require hospital monitoring to manage vital functions and observe for cardiac irregularities.

Therapeutic Uses of Tridosil

What Tridosil Treats: Main Uses and Benefits

Tridosil is used to provide essential therapeutic support across several clinical domains by managing symptoms related to physical discomfort. It is relevant for easing symptoms associated with various infections in the lungs, skin, and reproductive organs.

Therapeutic Scope

Tridosil is commonly used to help manage conditions presenting with acute or disruptive episodes, including community-acquired pneumonia, bronchitis, acute bacterial sinusitis, otitis media, and uncomplicated skin and skin structure infections. It is also applied within therapeutic regimens for specific sexually transmitted infections (STIs), such as those caused by Chlamydia trachomatis. Its application helps address symptom clusters like fever, worsening cough, localized pain, and genital inflammation.

“Tridosil is commonly used when symptoms intensify and supportive relief is needed across domains where acute manifestations interfere with function.”

In cases of Chronic Obstructive Pulmonary Disease (COPD), it is considered relevant for managing acute bacterial exacerbations. This use provides support that contributes to easing the overall symptom load and assists with maintaining functional stability during challenging symptomatic phases.

Quick Fact: Relief for Acute Infections
Symptom focus: Fever, localized pain, and respiratory discomfort.
Contextual benefit: Contributes to easing discomfort during periods of heightened symptoms associated with bacterial illness.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Tridosil?

Eligibility for Tridosil (Azithromycin) is determined by regulatory guidelines based on patient health and age. This medicine is generally prescribed for adults and children ge 6 months of age for approved indications. Use in elderly patients requires caution due to an increased risk of specific cardiac arrhythmias.


Absolute Non-Eligibility (Contraindications)

Tridosil must not be used if a patient has a known allergy (hypersensitivity) to azithromycin, erythromycin, or any macrolide/ketolide antibiotic. It is also contraindicated in individuals with a history of cholestatic jaundice or hepatic dysfunction that was linked to prior azithromycin use, or in patients with congenital or documented acquired QT prolongation.


Restricted or Conditional Use

Use is restricted or requires significant caution in several populations:

  • Infants under 6 months of age: Safety and effectiveness are not established for most labeled uses.
  • Severe Organ Impairment: Caution is necessary for patients with severe renal impairment or significant hepatic disease.
  • Cardiovascular Risk: The medicine is generally not recommended for patients with pre-existing conditions like uncorrected low potassium or certain cardiac arrhythmias.
  • Pregnancy and Breastfeeding: Use during pregnancy is advised only if clinically needed. Breastfeeding should typically be discontinued during treatment.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory documents define specific, documented interaction patterns for Tridosil (Azithromycin), including combinations that are formally restricted or require monitoring.

Contraindicated Combinations

The co-administration of Tridosil is officially prohibited with Pimozide and with Ergot Alkaloids (such as Ergotamine or dihydroergotamine). The restriction with Pimozide is based on the documented risk of additive QT interval prolongation and potential serious cardiac events.

Interactions Requiring Monitoring

Interacting Substance Officially Documented Outcome
Oral Anticoagulants (e.g., Warfarin) Potential for increased Prothrombin Time or INR, requiring mandated monitoring of coagulation parameters.
Digoxin or Ciclosporin May increase plasma concentrations of the co-administered drug, requiring mandated monitoring of their serum levels.
Nelfinavir Co-administration significantly increases Azithromycin plasma exposure (AUC and Cmax).

Administration-Timing Requirements

Aluminum- and Magnesium-containing Antacids reduce the peak plasma concentration of Tridosil and must be administered at least 2 hours apart. The capsule and oral suspension forms must be taken without food, whereas tablets may be taken with or without food. Caution is advised when used in patients with severe renal impairment due to increased systemic exposure.

Mechanism of Action

How Tridosil Works

Tridosil's mechanism of action is defined by two fundamental and complementary biological activities: the arrest of microbial growth and the modulation of the host's inflammatory response.


Blocking the Bacterial Assembly Line

This primary function acts as a protein synthesis inhibitor. The drug binds selectively and with high affinity to the 23S ribosomal RNA within the bacterial 50S ribosomal subunit. . By physically obstructing the nascent peptide exit tunnel, Azithromycin immediately blocks the elongation of essential protein chains, causing the arrest of bacterial replication (bacteriostasis). This mechanism is necessary for the resulting bacteriostatic effect, which allows the host's natural defense systems to clear the non-replicating microbial population.


Modulating Immune Cell Signaling

This secondary domain describes the drug's effect on the body's defense systems. Azithromycin actively accumulates in host phagocytic cells (like macrophages) where it acts as a modulator of intracellular signaling pathways. This activity leads to the suppression of pro-inflammatory cytokine release, resulting in the modulation of tissue inflammation. Furthermore, the drug can interfere with bacterial communication systems like quorum sensing, which also modulates a key virulence mechanism.

Dosage and Administration Information

How to Use Tridosil

Tridosil (Azithromycin) is administered via the oral route (as tablets, standard suspension, or extended-release suspension) or via intravenous (IV) infusion in hospital settings.

The standard adult usage pattern adheres to a once-daily frequency over a short course, typically 1500 mg total dose administered over three or five sequential days. The 5-day course starts with 500 mg on Day 1, followed by 250 mg daily on Days 2-5. For specific infections, a single 1 g oral dose is utilized. IV therapy often serves as a 1-2 day starter for severe conditions, followed by oral dosing to complete a total 7-10 day course.

Administration timing is dependent on the specific formulation:

  • Oral Tablets and Standard Suspension: May be taken with or without food.
  • Extended-Release Suspension: Must be taken on an empty stomach (at least 1 hour before or 2 hours after a meal).

The IV powder requires reconstitution and subsequent dilution before being administered as a slow infusion over a minimum of 60 minutes. Dosing for pediatric patients is calculated based on body weight (mg/kg), while adult patients with mild to moderate renal or hepatic impairment generally require no dose adjustment. If a dose is missed, the standard protocol involves taking it immediately unless it is nearly time for the next scheduled dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Tridosil


Evidence for Acute Respiratory Tract Infections

Research has extensively explored the use of Tridosil in individuals with acute bacterial infections within the respiratory system, such as Community-Acquired Pneumonia and bacterial Sinusitis, primarily through Randomized Controlled Trials (RCTs) and meta-analyses. These trials monitored outcomes related to symptom change in adult and pediatric populations. Findings describe patterns observed in the studies that were evaluated in relation to other established treatments. What remains uncertain is the need for more contemporary double-blind RCTs and the long-term impact on recurrent infections.


Evidence for Chronic Lung Disease Exacerbations

Tridosil was studied for its use in managing acute bacterial exacerbations of Chronic Obstructive Pulmonary Disease (COPD) through Placebo-Controlled Trials focused on maintenance therapy. Studies examined the frequency and timing of future exacerbation episodes. Long-term effects are not fully established, and subgroup data remain insufficient for patients with severe comorbidities. The potential for the emergence of antimicrobial resistance during long-term maintenance was noted as a research limitation.


Evidence for Skin and Sexually Transmitted Infections

Research, including RCTs and multicenter observational studies, evaluated Tridosil for Uncomplicated Skin Infections and specific STIs, such as those caused by Chlamydia trachomatis. Studies reported high measurements of microbiological and clinical cure rates for uncomplicated urogenital infections. However, comparative evidence is lacking for large-scale RCTs focusing on extragenital infections, and findings described varying outcomes measured at these sites.


Long-Term Studies and Follow-Up

Research has explored extended-term studies (up to 12 months or longer) for chronic conditions. Findings help contextualize patient experience during prolonged observation, but overall, there is limited information for long-term outcomes beyond the initial symptom resolution period for most acute uses.


Evidence in Special Populations

Tridosil was evaluated in studies examining patient-reported experiences for both adult and pediatric populations, including older adults. However, data for certain groups remain insufficient, and sample sizes were modest for specific elderly or fragile patient subgroups.


Research Gaps and Uncertainty

The existing research highlights several areas where certainty remains low or data are limited. Follow-up durations were limited in many studies, meaning research provides less insight into the durability of the response years later. Comparative evidence is lacking for some of the medicine's uses against newer therapeutic options, indicating that the results apply only to the populations studied.

Frequently Asked Questions (FAQ)

Common questions about Tridosil (FAQ)


Q: Is Tridosil considered a long-term medication?

A: Official prescribing information indicates that Tridosil is primarily used in short courses, often lasting just a few days, for most bacterial infections. While it has been studied for long-term use in specific chronic conditions, the decision regarding long-term use is made by a healthcare provider, who weighs the potential benefits and risks.

Q: What food or drinks should I avoid while on Tridosil?

A: Official information states that antacids containing aluminum or magnesium should not be taken at the same time, as they can reduce how much Tridosil your body absorbs. The oral tablets and standard suspensions can be taken with or without food. However, the extended-release suspension must be taken on an empty stomach, generally one hour before or two hours after a meal.

Q: What happens if I accidentally miss a dose of Tridosil?

A: Official guidance indicates that the missed dose should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule resumed. It is important not to take a double dose to compensate for the missed one.

Q: What should I do if the side effects from Tridosil seem bothersome?

A: If signs of a serious reaction occur, such as a severe allergic reaction or symptoms of hepatitis (liver issues), official documentation advises that the drug should be stopped immediately. For common side effects that are simply bothersome, official documents advise contacting a healthcare professional for guidance.

Q: Does Tridosil interact with birth control pills?

A: Studies noted in the prescribing information indicate that Azithromycin (the active ingredient in Tridosil) does not appear to affect the efficacy of most oral contraceptive pills. It is important for patients to inform their healthcare provider about all medications they are taking.

Q: Is it safe to take Tridosil while breastfeeding?

A: Azithromycin is known to pass into human breast milk. The decision to continue or discontinue nursing, or to stop the medication, must be made by a healthcare provider after carefully considering the potential risk to the infant versus the importance of the drug to the mother’s health. The patient should discuss the use of this medicine with their healthcare provider.

Q: Is it normal to feel a little nauseous when first starting Tridosil?

A: Nausea is listed as a common side effect in the official safety profile. Regulatory information notes that gastrointestinal disturbances, like nausea, may be more common at the start of treatment.

Q: Will Tridosil affect my ability to drive or operate machinery?

A: There are no specific data on whether Tridosil impairs driving ability. However, reported side effects include dizziness, which could potentially impact concentration. Patients are cautioned to be aware of how the medicine affects them before driving or operating machinery. If side effects like dizziness occur, it is important to consult a healthcare provider.

Q: Is there a generic version of Tridosil available yet?

A: Yes. Tridosil’s active ingredient is Azithromycin, which is the generic name for the medicine. Azithromycin is widely available in generic formulations, according to regulatory listings.

Q: Does Tridosil have any impact on blood pressure?

A: Although rare, official regulatory documents list hypotension (low blood pressure) as a potential adverse reaction. Tridosil also carries warnings about serious cardiac effects, which highlights the need for caution. Patients with pre-existing heart conditions are advised to use caution, and any concerns should be discussed with a healthcare provider.

Q: Is Tridosil meant to cure a condition or just manage symptoms?

A: Tridosil is an anti-infective agent indicated to treat bacterial infections. Its primary action is to interfere with the bacteria's ability to create essential proteins, which halts the growth of the harmful microorganisms and allows the body's natural defenses to eliminate the infection.

Q: Does Tridosil need to be taken with food?

A: This depends on the specific form. Oral tablets and standard liquid suspensions can be taken with or without food. However, the extended-release liquid suspension must be taken without food on an empty stomach.

Q: How is Tridosil stored, and what is its shelf life?

A: Tablets and the dry powder must be kept at a controlled room temperature. Once the liquid suspension is mixed, official documents advise that it must be discarded after 10 days. The intravenous (IV) solution also has a limited stability period. All forms must be stored in the original container and out of sight and reach of children.

Q: Is Tridosil used to treat inflammation?

A: While Tridosil is primarily an antibiotic, its mechanism of action includes a secondary effect described in official documents. It can modulate the host's inflammatory response by affecting immune cell signaling pathways.

Q: Will Tridosil affect the results of standard blood tests?

A: Official labeling notes that in clinical trials, some patients experienced changes in laboratory values. These changes can include elevated levels of liver enzymes (AST and ALT) and variations in white blood cell counts or markers of kidney function.

Q: What happens if I stop taking Tridosil suddenly?

A: Stopping the medicine too soon can increase the risk of treatment failure, meaning the infection may not be completely eliminated. Furthermore, prematurely discontinuing antibiotic use is a factor that can contribute to the development of drug-resistant bacteria.

Q: Does Tridosil interact with antacids or heartburn medicines?

A: Yes, it can. Antacids that contain aluminum or magnesium reduce how much Tridosil gets absorbed into the body. To prevent this interaction, these antacids and Tridosil must be taken at least two hours apart.

Q: Does Tridosil have any effect on sleep patterns?

A: The official safety profile lists insomnia (difficulty sleeping) as an uncommon side effect. Any changes in sleep patterns should be discussed with a healthcare professional.

How should Tridosil be stored and disposed of?

How to Store and Dispose of Tridosil (Azithromycin)

The medicine's storage and handling requirements depend on the specific form (tablet, suspension, or IV solution) and must adhere strictly to official regulatory labeling.

Storage Conditions and Stability

Tridosil tablets and dry powder must be stored at controlled room temperature and protected from excess heat and moisture. The oral suspension, once mixed, must be stored between 5 C and 30 C and must not be frozen.

Dosage Form Stability Rule After Preparation
Oral Suspension Discard any unused portion after 10 days.
IV Solution (Diluted) Stable for 7 days under refrigeration or 24 hours at room temperature.

All forms of Tridosil must be kept in the original container, tightly closed, and stored out of the sight and reach of children.

Disposal

Any unused or expired product must be disposed of according to local regulations. Unused portions of the liquid suspension must be discarded after the stated stability period.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tridosil found in:

A-Z Index: